Lecture by: Maheen Mausoof Adamson, PhD, MHL (CEO & Founder, Soof Solutions/Clinical Professor (affiliated) Neurosurgery, Stanford School of Medicine)

A recent executive order signed on April 18, 2026, by POTUS, directed federal agencies to accelerate research and expand access pathways for psychedelic medicines, including ibogaine. The order represents a meaningful step toward evaluating novel treatments for conditions such as traumatic brain injury (TBI), post-traumatic stress disorder (PTSD), and substance use disorders that have long been underserved by existing therapies. The Adamson Lab is committed to meeting this moment with the scientific rigor these questions demand.

Brain Stimulation Lab (BSL) ibogaine research program at Stanford was pioneered by the late Nolan Williams, whose landmark 2024 Nature Medicine study of magnesium-ibogaine therapy in Special Operations veterans with TBI helped bring this compound into mainstream scientific conversation. Along with Dr. Adamson’s team, BSL also collected the first-ever human neuroimaging data on ibogaine as part of that study. Ongoing and planned studies include deeper mechanistic investigations of ibogaine’s effects on brain network dynamics, as well as a newly planned study examining ibogaine-assisted therapy for war-related PTSD. 

This talk will cover the history of ibogaine as a psychedelic, safety, cultural accuracy, medical ethics and what is needed to provide it to those who need it the most.

6:30pm: Networking

7pm: Lecture

8pm: Q&A

Host: Naeem Zafar '81